lm-102
mAbexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 16, 2021 (NCT04735796)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Claudin-18ADCC
CLDN18 adcc
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05008445 | Phase 1/Phase 2 (Phase 2) | Oct 6, 2021 | Fudan University, Harbin Medical University, LaNova Medicines Limited, Zhejiang University |
| NCT04735796 | Phase 1 | Jun 16, 2021 | LaNova Medicines Limited |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| LaNova Medicines Limited | For profit | 2 | 2 | 2 | 2021 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Harbin Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1